The manuscript, titled, 'Radiation therapy induces innate immune responses in patients treated for prostate cancers,' by Dr. Amrita K Cheema, was published in
The report provides insight into the immune response taking place in patients after radiation therapy for cancer. These data inform potential development of biomarkers of radiation response and therapeutic strategies for sequencing radiation and immune therapy modalities for cancer treatment,' commented
Radiation therapy (RT) is a curative therapeutic modality used to treat cancers as a single agent or in combination with surgery and chemotherapy. To understand systemic clinical responses after radiation exposure, proteomic and metabolomic analyses were performed on plasma obtained from cancer patients at intervals after prostate radiation therapy.
DNA Damage Response (DDR) increased within the first hour after treatment and returned to baseline by one month. Robust immune signaling also increased within one hour of treatment but persisted for up to three months thereafter.
The data support innate immune activation as a critical clinical response of patients receiving radiation therapy for prostate cancer, potentially informing multidisciplinary therapeutic strategies for cancer treatment.
The study was supported by NIH SBIR Contracts HHSN261201600027C and 75N81018C00031 to
The journal
About
Founded in 2012 by faculty members of the
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's IPO prospectus filed with the
Contact:
Tel: 240-403-4212
Email: info@shuttlepharma.com
(C) 2023 Electronic News Publishing, source